Thank you very much.
I'd like to direct my question to Ms. Chan. My colleague Mr. Sorbara asked a bit about recommendation three. I apologize, but I'm still not clear. What specifically is the government looking to propose in this new regulation? What specifically will impede or cause difficulties for pharmaceutical competitiveness?